DNA Funded and HyroTrader occupy the same budget tier of the prop firm market but serve entirely different asset classes, making this less a head-to-head rivalry than a fork-in-the-road decision based on what you actually trade. DNA Funded, backed by the ASIC-regulated broker DNA Markets, built its value proposition around CFD and equity breadth: 800-plus instruments at entry prices starting near $25. HyroTrader took the opposite specialization, focusing entirely on crypto and differentiating itself with real exchange execution through Bybit and Binance rather than a firm-run simulated feed, a genuinely unusual level of execution transparency in a sector where most challenges run on opaque internal pricing. Both firms are still building their long-term Trustpilot track records, with DNA Funded showing a volatile 3.4-3.9 range across trackers and HyroTrader sitting more consistently around 4.0-4.5 from a similarly modest review base.
The problem: The core friction for traders weighing these two firms is that neither has fully resolved its category’s biggest structural complaint. DNA Funded’s single-day profit distribution rule generates the same kind of trader frustration seen across the budget CFD tier — reviewers describe confusion around payout eligibility when a large share of profit came from one strong session, and the firm’s limited TradeLocker-only platform choice means traders can’t simply switch to a more familiar interface if execution quality becomes a concern. HyroTrader’s honest weakness is its profit-split economics: a 70% starting split is meaningfully below nearly every competitor in the crypto prop space, meaning the first four months of funded trading cost a HyroTrader trader more in absolute terms than almost any comparable firm, a trade-off the firm’s real-exchange-execution transparency doesn’t fully offset for traders focused purely on take-home profit. Both firms’ 40%-and-25%-style consistency rules also mean traders relying on one large winning day, rather than steady daily gains, will find either firm’s payout math working against them.
Quick Comparison
| DNA Funded | HyroTrader | |
|---|---|---|
| Starting Price | $25 per challenge | $59 per challenge |
| Rating | 3.9 / 5 | 4.3 / 5 |
| Free Trial | No | No |
| Best For | Budget CFD and equity traders who want broker-backed execution credibility at the lowest possible entry cost | Crypto-only traders who want real exchange execution rather than a firm-run simulated price feed |
| Ease of Use | 7 / 10 | 6 / 10 |
| Support Rating | 7 / 10 | 7 / 10 |
| Mobile App | No | No |
| Start DNA Funded’s $25 Challenge → | Test HyroTrader’s Real-Execution Model → |
Pros & Cons
- Backed by DNA Markets, an ASIC-licensed liquidity provider, adding broker credibility rare at this price tier
- Access to 800+ tradeable instruments including global equities and indices most forex-first firms don’t offer
- Five challenge formats including a $25 24-Hour Challenge and a 10-day Rapid Challenge for fast entries
- Crypto and card payment options with a straightforward 14-day payout cycle
- Standard profit split is capped at 80% until a 20% Profit Split Booster add-on unlocks 90%
- Limited platform choice: only TradeLocker and a TradingView web integration, no MT5 or cTrader
- No second chance on a drawdown breach; the account terminates immediately without a warning buffer
- Real exchange execution via Bybit and Binance through its proprietary CLEO platform, letting traders independently verify every fill against the live order book
- Challenge fee is fully refunded on the first funded payout, aligning the firm’s incentives with trader retention
- Six USDT-denominated account sizes from $5,000 to $200,000, scaling to $1,000,000 with consistent performance
- Founded in 2022 with a documented multi-year operating history in the crypto prop niche specifically
- Profit split starts lowest in its category at 70%, only reaching 80% by month eight and 90% at month twelve or beyond
- 40% consistency rule during evaluation limits how much of total eval profit can come from a single day
- $200,000 maximum funded capital ceiling is lower than several crypto-focused competitors, which scale to $600K-$2M
Feature-by-Feature Breakdown
| Feature | DNA Funded | HyroTrader | Winner |
|---|---|---|---|
| Entry Price | $25 (24-Hour Challenge) | $59 (discounted tiers available) | DNA Funded |
| Starting Profit Split | 80% standard | 70%, scaling to 90% over 16 months | DNA Funded |
| Max Funded Allocation | $600,000 | $200,000 (scales to $1,000,000) | DNA Funded |
| Execution Model | Simulated via TradeLocker/broker feed | Real exchange execution via Bybit/Binance | HyroTrader |
| Instrument Coverage | 800+ (forex, stocks, indices, commodities, crypto CFDs) | Crypto only | DNA Funded |
| Integrations | TradeLocker, TradingView web integration; crypto and card payment processing | Bybit, Binance (via proprietary CLEO platform); real exchange order execution | — |
Final Verdict
Winner: DNA Funded
Frequently Asked Questions
Why is HyroTrader’s starting profit split only 70%?
HyroTrader structures its profit split to scale with trader tenure rather than offering a flat rate from day one, starting at 70% and rising to 80% around month eight and 90% from month twelve onward, according to proptradingvibes.com’s 2026 analysis. The firm frames this as aligning incentives with long-term trader retention, though it does mean early-stage funded traders keep less of their profit than at most competitor firms.
Does DNA Funded offer real exchange execution like HyroTrader?
No, DNA Funded operates on a more conventional CFD prop firm model via TradeLocker, with pricing and execution backed by its broker partner DNA Markets rather than a direct, independently verifiable exchange order book connection. This is a genuine structural difference from HyroTrader’s Bybit/Binance-based CLEO platform, which is built specifically around exchange-verifiable execution.
Is HyroTrader regulated or licensed?
HyroTrader is not described as a regulated broker in available independent reviews; like most prop firms, it operates simulated or exchange-linked funded accounts outside traditional financial regulation. Its real-exchange execution via Bybit and Binance provides a form of technical transparency, but this is distinct from formal regulatory oversight.
Can I trade stocks or indices at HyroTrader?
No, HyroTrader is explicitly a crypto-only prop firm, with all six of its account tiers denominated in USDT and its CLEO platform built specifically around crypto exchange connectivity. Traders who want stock, index, or forex exposure alongside crypto should consider a multi-asset firm like DNA Funded or FundedNext instead.
Which firm has the more reliable Trustpilot rating?
Both firms have relatively small, still-developing review bases, but HyroTrader’s rating has shown more consistency (roughly 4.0-4.5 across multiple trackers) than DNA Funded’s, which has ranged more widely from 3.4 to 3.9 depending on the source and snapshot date. Neither firm yet has the review volume of established names like FTMO or FundedNext, so traders should treat both ratings as directionally useful rather than statistically definitive.